This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cone, L A
Right arrow Articles by Byrd, R G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cone, L A
Right arrow Articles by Byrd, R G

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1985 July; 28(1): 33-36

Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia.

L A Cone, D R Woodard, D S Stoltzman and R G Byrd

ABSTRACT

A prospective, randomized study was undertaken to compare the efficacy and safety of ceftazidime with those of a combination of ticarcillin and tobramycin in the treatment of 40 nonneutropenic patients with pneumonia or bacteremia. Altogether, 93% of the patients receiving ceftazidime for pneumonia were cured, and 87% of those with bacteremia responded favorably. Of the subjects who were treated with ticarcillin and tobramycin ceftazidime developed significant superinfection, and one individual treated with the aminoglycoside and carboxypenicillin developed reversible azotemia. Ceftazidime appears to be as efficacious as the ticarcillin-tobramycin combination and is probably safer with regard to oto-and nephrotoxicity; however, superinfections did occur more frequently in the group treated with ceftazidime.

Antimicrob Agents Chemother. 1985 July; 28(1): 33-36




This article has been cited by other articles:

  • Masterton, R. G., Galloway, A., French, G., Street, M., Armstrong, J., Brown, E., Cleverley, J., Dilworth, P., Fry, C., Gascoigne, A. D., Knox, A., Nathwani, D., Spencer, R., Wilcox, M. (2008). Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 62: 5-34 [Abstract] [Full Text]  
  • Paul, M., Benuri-Silbiger, I., Soares-Weiser, K., Leibovici, L. (2004). {beta} lactam monotherapy versus {beta} lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328: 668- [Abstract] [Full Text]  
  • FAGON, J.-Y., PATRICK, H., HAAS, D. W., TORRES, A., GIBERT, C., CHEADLE, W. G., FALCONE, R. E., ANHOLM, J. D., PAGANIN, F., FABIAN, T. C., LILIENTHAL, F., the Nosocomial Pneumonia Group, (2000). Treatment of Gram-positive Nosocomial Pneumonia . Prospective Randomized Comparison of Quinupristin/Dalfopristin versus Vancomycin. Am. J. Respir. Crit. Care Med. 161: 753-762 [Abstract] [Full Text]  
  • Joshi, N., Milfred, D. (1995). The Use and Misuse of New Antibiotics: A Perspective. Arch Intern Med 155: 569-577 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»